نتائج البحث - "Sossana Delimpasi"

1

دورية أكاديمية

المؤلفون: Fredrik H. Schjesvold, Heinz Ludwig, Sossana Delimpasi, Pawel Robak, Daniel Coriu, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Meletios-Athanasios Dimopoulos, Tamas Masszi, Natalia G. Chernova, Anna Sandberg, Marcus Thuresson, Stefan Norin, Nicolaas A. Bakker, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld

المصدر: Haematologica, Vol 999, Iss 1 (2024)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11485Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/1f56d919430f4d45b42e8c04712262cbTest

View record in DOAJ

النص الكامل

2

دورية أكاديمية

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

المؤلفون: Maria Victoria Mateos, Katja Weisel, Evangelos Terpos, Sossana Delimpasi, Efstathios Kastritis, Elena Zamagni, Michel Delforge, Enrique Ocio, Eirini Katodritou, Francesca Gay, Alessandra Larocca, Xavier Leleu, Paula Rodriguez Otero, Fredik Schjesvold, Michele Cavo, Meletios A. Dimopoulos

المصدر: Haematologica, Vol 999, Iss 1 (2024)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/11470Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/d32b963c3bd94ba795f5046d7984d202Test

View record in DOAJ

النص الكامل

3

دورية أكاديمية

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

المؤلفون: Efstathios Kastritis, Marie-Christine Kyrtsonis, Pierre Morel, Maria Gavriatopoulou, Evdoxia Hatjiharissi, Argirios S. Symeonidis, Amalia Vassou, Panagiotis Repousis, Sossana Delimpasi, Anastasia Sioni, Evrydiki Michalis, Michail Michael, Elina Vervessou, Michael Voulgarelis, Costantinos Tsatalas, Evangelos Terpos, Meletios A. Dimopoulos

المصدر: Haematologica, Vol 100, Iss 11 (2015)

مصطلحات موضوعية: Diseases of the blood and blood-forming organs, RC633-647.5

وصف الملف: electronic resource

العلاقة: https://haematologica.org/article/view/7566Test; https://doaj.org/toc/0390-6078Test; https://doaj.org/toc/1592-8721Test

الوصول الحر: https://doaj.org/article/55bc2969454f4c1da6f7bb2084ba77f2Test

View record in DOAJ

النص الكامل

4

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

المؤلفون: Magdalini Migkou, Maria Roussou, Evangelos Terpos, Maria Gavriatopoulou, Panagiotis Tsirigotis, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Ioanna Dialoupi, Mairylin Spyropoulou-Vlachou, Nikolaos Kanellias, Sossana Delimpasi, Dimitrios C. Ziogas, Aikaterini Xirokosta, Despina Fotiou, Despina Mparmparousi, Stavroula Giannouli, Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos

المصدر: Blood Advances. 3:4095-4103

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45f37149bd87c9c9bac049215856047Test
https://doi.org/10.1182/bloodadvances.2019000539Test

5

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

المؤلفون: E. Rivolti, E. Hatjiharissi, M.A. Dimopoulos, N. Kanellias, Despina Fotiou, Argiris Symeonidis, Maria Roussou, Sossana Delimpasi, E. Zamagni, Maria Gavriatopoulou, E. Terpos, Magdalini Migkou, E. Katodritou, M. Cavo, Marie-Christine Kyrtsonis

المصدر: Hematology, Transfusion and Cell Therapy, Vol 42, Iss, Pp 22-23 (2020)

مصطلحات موضوعية: Oncology, medicine.medical_specialty, lcsh:RC633-647.5, business.industry, Daratumumab, lcsh:Diseases of the blood and blood-forming organs, Hematology, medicine.disease, Internal medicine, Relapsed refractory, medicine, Immunology and Allergy, In patient, business, Dexamethasone, Multiple myeloma, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb32d8b7cfd2b97f20633b68f64747beTest
https://doi.org/10.1016/j.htct.2020.09.043Test

6

Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group

المصدر: Clinical Lymphoma Myeloma and Leukemia. 19:e190-e191

مصطلحات موضوعية: Cancer Research, Oncology, Hematology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::22951d94bc2fc200493a6687cf9e3020Test
https://doi.org/10.1016/j.clml.2019.09.318Test

7

Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis

المؤلفون: Sandrine Macé, Kazutaka Sunami, Michel Attal, Paul G. Richardson, Sossana Delimpasi, David Simpson, Cyrille Hulin, Frank Campana, Thierry Facon, Simon J. Harrison, Helgi van de Velde, Adrian Alegre, Andrew Spencer, Philip Vlummens, Kwee Yong, Marlène Inchauspé, Marie-Laure Risse, Ming Chung Wang

المصدر: Clinical Lymphoma Myeloma and Leukemia. 19:e33

مصطلحات موضوعية: Isatuximab, Oncology, Cancer Research, medicine.medical_specialty, business.industry, Cytogenetics, Subgroup analysis, Hematology, medicine.disease, Pomalidomide, Internal medicine, Relapsed refractory, Medicine, business, Dexamethasone, Multiple myeloma, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1562bdcb90851c8745b7bdae3086f806Test
https://doi.org/10.1016/j.clml.2019.09.049Test

8

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

المصدر: Blood Cancer Journal
Blood Cancer Journal, Vol 8, Iss 3, Pp 1-8 (2018)

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, lcsh:RC254-282, Disease-Free Survival, Article, Leukemia, Plasma Cell, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Autologous stem-cell transplantation, Internal medicine, medicine, Humans, Autografts, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, Plasma cell leukemia, Univariate analysis, Greece, business.industry, Mortality rate, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 3. Good health, Survival Rate, Clinical trial, Leukemia, 030220 oncology & carcinogenesis, Female, business, Stem Cell Transplantation, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f010ddd4477672420258ab6d7af450Test
https://doi.org/10.1038/s41408-018-0059-6Test

9

Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group

المؤلفون: Charikleia Kelaidi, Marie-Christine Kyrtsonis, Sossana Delimpasi, Evgenia Verrou, Nikos Giannakoulas, Pavlina Konstantinidou, Eirini Katodritou, Maria Kotsopoulou, Kostas Zervas, Argiris Symeonidis, Christina Chatziaggelidou, Evangelos Terpos, Aikaterini Stefanoudaki, Nikos Spyridis, Meletios A. Dimopoulos, Vassiliki Gastari, Dimitrios Christoulas

المصدر: American Journal of Hematology. 89:145-150

مصطلحات موضوعية: Oncology, Very Good Partial Response, Plasma cell leukemia, medicine.medical_specialty, business.industry, Bortezomib, Hematology, medicine.disease, Surgery, Overall response rate, Plasma cell disorder, Internal medicine, Toxicity, medicine, Autologous transplantation, In patient, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::fc172667bad44330c6cc0504c952a89aTest
https://doi.org/10.1002/ajh.23600Test

10

Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

المصدر: Hematological Oncology. 31:96-102

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9fe2159a9a73251735f6e9970ff4d5e1Test
https://doi.org/10.1002/hon.2026Test

تنقيح النتائج